New Delhi: Australian researchers have developed a lightweight, waterproof heart monitor that can continuously record the heart’s electrical activity for up to 14 days. The device could make cardiac monitoring more comfortable and accessible, particularly for patients in areas with limited access to healthcare.
Developed at RMIT University and now being commercialised by Australian start-up Lubdub, the device has entered clinical testing at Midlands Medical Specialists in Perth, Western Australia.
According to a university announcement on 19 November, the wireless patch is designed to provide information comparable to that obtained from conventional electrocardiogram (ECG) Holter monitors, without being as bulky or intrusive on patients’ everyday activities.
Holter monitors are portable devices that record the heart’s electrical activity over an extended period while patients go about their daily routines. This helps doctors detect irregular heart rhythms that may not show up during a routine ECG, which typically records cardiac activity over a much shorter period.
However, conventional Holter monitors require multiple electrodes and wires to be attached to the body, which can make prolonged monitoring uncomfortable.
Cleaner signals without conductive gel
The new monitoring patch uses flexible sensors that maintain contact with the skin without requiring conductive gel, which is commonly used with conventional electrodes to improve signal reception.
“The flexible sensors make better contact with the skin,” said RMIT professor and Lubdub co-founder Sharath Sriram.
Preliminary tests involving healthy volunteers produced ECG recordings that were 18 times cleaner than those obtained using conventional Holter monitors. Participants also reported that the prototype was more comfortable to wear.
Sriram estimated that reducing the time and effort required to prepare monitoring equipment could allow existing healthcare personnel to monitor up to 85 per cent more patients, even before introducing additional technologies such as artificial intelligence.
The ongoing clinical trial aims to recruit 100 adults with suspected heart rhythm abnormalities. Participants will wear the prototype alongside an established ECG monitor for 24 to 48 hours, allowing researchers to compare the devices’ recording accuracy, signal quality, comfort and usability.
Also read: Cardiac arrest, irregular rhythms—new study links energy drinks to heart problems
Towards more accessible cardiac testing
The technology builds on research published in 2023, when RMIT scientists demonstrated a compact ECG sensor using three dry electrodes.
“Dry electrodes prioritise user comfort,” researcher Peter Elango said at the time, highlighting their suitability for prolonged monitoring.
Lubdub ultimately plans to combine the ECG patch with non-invasive cardiac biomarker testing and wearable ultrasound imaging, potentially allowing patients to undergo multiple cardiac assessments through a single diagnostic platform.
Co-founder Nikhilesh Bappoo said his motivation to develop the technology was partly shaped by his father’s heart attack in Perth, where timely access to specialist care was available. Having grown up in Mauritius, he had also witnessed the differences in healthcare access between the two places.
The company hopes the technology will help reduce delays in diagnosing cardiovascular conditions, particularly in rural and underserved regions.
The clinical trial is still underway and will assess the device’s performance in patients with suspected heart rhythm abnormalities.
(Edited by Maryam Hassan)
